AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02548000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
Study NCT02548000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching control
Description: The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
Study NCT04833725 — intervention group
Intervention type: DEVICE
Intervention: wearable devices
Description: All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
Study NCT00387010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablets
Description: Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily.
Study NCT02556619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Palliative Care/Symptom Control
Description: 1. Establish palliative care goals~   1. Determination of Medical Power of Attorney~  2. Discuss/plan code status/advance directives~  3. Document palliative care goals~2. Symptom Assessment and Control~   1. Pain-treatment with opioid and non-opioid medications~  2. Itching-H2 blockers, steroids~  3. Nutrition-appetite stimulated with Megace, review low sodium diet~  4. Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~  5. Nausea- treated with anti-emetics~  6. Jaundice and Body Image- counselling regarding symptoms~3. End-of-Life Care~   1. Discuss religious preferences~  2. Assess for distress- ensure interaction with Cancer Resource Center~  3. Hospice- charity Hospice options for select patients.
Study NCT03931317 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprostene bunod 0.024% QD
Description: This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
Study NCT03931317 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Timolol maleate 0.5% BID
Description: This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
Study NCT03603470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EOS imagery
Description: Whole body EOS imaging in seated and standing position
Study NCT03265548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Laryngoscope
Description: The use of video laryngoscopy
Study NCT00705718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endurant Stent Graft System
Description: Abdominal Aortic Aneurysm Repair
Study NCT04965441 — intervention group
Intervention type: PROCEDURE
Intervention: Computer-assisted surgery
Description: Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness\<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
Study NCT01243502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% CT327 (or placebo)
Description: Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
Study NCT01243502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.001% CT327 (or placebo)
Description: Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
Study NCT02416531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate
Description: Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
Study NCT02416531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
Study NCT02416531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
Study NCT03104426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
Study NCT02008747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
Study NCT01385488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitor arm volume
Description: bioelectrical impedance
Study NCT02580474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus Asunaprevir
Study NCT02231593 — intervention group
Intervention type: OTHER
Intervention: SAGIT
Description: SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
Study NCT04599933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF-1
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study NCT04599933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study NCT03890627 — intervention group
Intervention type: DEVICE
Intervention: Thoracic bio-reactance
Description: Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
Study NCT02167815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex XT
Description: Experimental arm
Study NCT02167815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Study NCT00483106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin
Description: 0.25 mg/kg bid, orally for 7 consecutive days
Study NCT00483106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taken orally twice a day for 7 consecutive days
Study NCT03811327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero-time Exercise
Description: A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
Study NCT02129790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Therapy
Description: Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
Study NCT03129282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Metacognitive Therapy (Home-MCT)
Description: Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
Study NCT03837964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet
Study NCT01758978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Study NCT02521532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study NCT02521532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study NCT04264117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FlexAbility (Mesh-like irrigated tip catheter) group
Description: 1. AF catheter ablation (PV isolation and linear ablations)~2. 30 sec ablation in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 13mL/min~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines
Study NCT04264117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TactiCath (Contract force monitoring catheter) group
Description: 1. AF catheter ablation (PV isolation and linear ablations)~2. contact force >10g, target force-time integral 400 in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines
Study NCT02872857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match drug capsules.
Study NCT02872857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8mg galantamine twice daily
Description: Drug will be administered within 36 hours of hospitalization and continued for 90 days.
Study NCT02872857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12mg galantamine twice daily
Description: Drug will be administered within 36 hours of hospitalization and continued for 90 days.
Study NCT01848236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Ergocalciferol vitamin D2
Study NCT01848236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol vitamin D2
Study NCT01825174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ball games program
Description: twice a week different ball games 90min
Study NCT01825174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ball games program
Description: twice a week different ball games 90min
Study NCT01825174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: 9 units of 90min each of nutrition counseling
Study NCT00460265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM 2
Description: Subjects will receive Cisplatin plus 5FU
Study NCT00460265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM 1
Description: Subjects will receive Panitumumab plus cisplatin and 5FU
Study NCT01623973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific training of paretic upper limb
Description: nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
Study NCT01623973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: specific training of paretic upper limb
Description: nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
Study NCT04544228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine + neostigmine
Description: 30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
Study NCT04544228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine +saline
Description: 30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
Study NCT01376466 — intervention group
Intervention type: OTHER
Intervention: CT scanning
Description: CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
Study NCT02951910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ophylosa tear supplement
Description: Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
Study NCT03434236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low dose Lipinova (30 mL daily)
Description: Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
Study NCT03434236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have a similar appearance, smell and taste as the nutritional supplement
Study NCT03434236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high dose Lipinova (60mL)
Description: Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
Study NCT02801474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct fracture reduction and fixation
Description: In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
Study NCT02801474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect fracture reduction and fixation
Description: In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
Study NCT03452020 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer
Description: Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
Study NCT00983489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video demonstration
Description: video will be shown to mothers
Study NCT00983489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counselling
Description: breast feeding counselling
Study NCT01941550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cabazitaxel chemotherapy
Description: given in 6 cycles
Study NCT04360122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole
Description: Levamisole (150 mg/day for two days per week for 2 months
Study NCT04360122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoprinosine
Description: Isoprinosine (1 g 3 times per day daily) for two months
Study NCT04360122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole and Isoprinosine
Description: Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
Study NCT04888702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Study NCT01745315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced bipolar devices
Study NCT04083963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
Study NCT04083963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel will be given weekly along with carboplatin for 12 weeks.
Study NCT04083963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
Study NCT04083963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
Study NCT03414788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF 06687234
Description: Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
Study NCT03414788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [124I]IB PF 06687234
Description: Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
Study NCT03743363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame 2/week
Description: virtual training 2 times a week(8 week-long)
Study NCT03743363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming 3/week
Description: virtual training 3 times a week(8 week-long)
Study NCT03743363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy control / Exergaming 1/week
Description: In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
Study NCT01054872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA plasmid vaccine
Description: 4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
Study NCT01054872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant Ad5 vaccine
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
Study NCT00291655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study